CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
Revusiran (ALN-TTRSC)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02292186
NCT02292186Phase 2Completed
CompareCT.gov

A Phase 2, Open-label Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis Who Have Previously Received ALN-TTRSC

Alnylam Pharmaceuticals·interventional·Posted Nov 17, 2014·Updated Jul 9, 2020

In Brief

A Phase 2 clinical trial evaluating Revusiran (ALN-TTRSC) for TTR-mediated Amyloidosis. Completed, enrolled 25 participants across 5 sites in 3 countries.

Detailed Summary

The purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being followed-up for safety.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTTR-mediated Amyloidosis
CountriesCanada, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 17, 2014
Enrollment StartOct 1, 2014
Primary CompletionFeb 22, 2017
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 11.6 years ago

Interventions

Revusiran (ALN-TTRSC)drug